Denali Therapeutics Inc.
Nasdaq DNLI · South San Francisco, CA
Works in Dermatology · Genetic & rare · Metabolic & endocrine · Neurology · Psychiatry
Denali Therapeutics Inc. is a clinical trial sponsor based in South San Francisco, CA, listed as Nasdaq DNLI. It has 9 active clinical trials with 644 planned participants, across 5 therapeutic areas. Since 2021 it has completed 7 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq DNLI
Fundraising
Pipeline · 9 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Denali Therapeutics Inc
Denali Therapeutics Inc is lead sponsor of 9 active clinical trials on ClinicalTrials.gov, with 644 planned participants, in Dermatology, Genetic & rare, Metabolic & endocrine, Neurology and other areas. Since 2021 it has completed 7 trials and stopped 0 early.
Denali Therapeutics Inc is based in South San Francisco, CA and is listed as Nasdaq DNLI. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Denali Therapeutics Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-09.
Approve Suite is not affiliated with Denali Therapeutics Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.